<DOC>
	<DOCNO>NCT01793025</DOCNO>
	<brief_summary>The purpose study assess safety efficacy infuse immune cell donor treatment patient acute myeloid leukemia resistant chemotherapy experience relapse . Unlike standard bone marrow stem cell transplantation use donor well 'matched ' patient , study use donor whose immune cell compatible patient . With standard stem cell bone marrow transplantation , well-matched immune cell attack leukemia also attack patient 's organ ( situation call graft-versus-host disease , persist long term ) . Our hypothesis mismatch donor cell fight leukemia eliminate patient 's body , long-term side effect like graft-versus-host disease occur .</brief_summary>
	<brief_title>Mismatched Donor Cells Treat Acute Myeloid Leukemia</brief_title>
	<detailed_description>The ATAC cell therapy product contains unselected , non-mobilized peripheral blood mononuclear cell related donor mismatch recipient 3 ( 6 ) HLA locus . Cohorts 3 patient treat four pre-specified dose level ( T cell per kg recipient weight ) . One ATAC infusion administer 24-48 hour follow re-induction chemotherapy ( relapsed primary refractory AML patient remission ) . In situation ATAC infusion available immediately follow re-induction chemotherapy patient nonetheless achieve complete remission , one ATAC infusion give 24-48 hour consolidation chemotherapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Recipient Age ≥ 18 year ( upper age limit , physician discretion advise ) AML refractory 2 course induction therapy ( together constitute 'firstline ' therapy ) relapse period morphologic complete remission morphologic remission incomplete blood count recovery ( CRi ) Candidacy intense induction chemotherapy ( ECOG 02 , adequate renal , liver cardiac function , absence uncontrolled infection ) Availability parent , sibling child HLA haploidentical ( homozygous share haplotype ) , deem suitable donor medical evaluation , complete peripheral blood mononuclear cell collection No history autologous allogeneic stem cell transplant , purine analog chemotherapy cyclophosphamide , total body irradiation Ability comprehend investigational nature study provide inform consent Recipient Acute promyelocytic leukemia ( include nonclassical rearrangement RARα ) History severe myelodysplastic syndrome clearly precede diagnosis AML ( i.e. , red cell transfusion dependence erythropoietin dependence 4month period , absence clear cause , follow : hemoglobin consistently 9 g/dL platelet 50 x 10^9/L ANC 1000/uL 2 occasion 2 week apart , use GCSF maintain ANC threshold absence infection , 3 month precede diagnosis AML ) . Exception : If ATAC therapy consider bridge stem cell transplantation patient available standard transplant donor ( familial , unrelated , cord blood ) , exclusion criterion apply . Grade 23/3 fibrosis diagnostic bone marrow biopsy DLCO &lt; 40 % predict Left ventricular ejection fraction &lt; 40 % ( evaluate ECHO MUGA ) AST/SGOT &gt; 2.5 x ULN Bilirubin &gt; 1.5 x ULN Creatinine &gt; 1.5 x ULN Creatinine clearance &lt; 50 mL/min HIV positive Major anticipate illness organ failure incompatible survival chemotherapy Concurrent second primary cancer prior malignancy require cytotoxic treatment within past 12 month , cervical carcinoma insitu prostate cancer insitu Severe psychiatric illness mental deficiency sufficiently severe make compliance treatment unlikely informed consent impossible Any congenital acquire immunodeficiency would possibly permit permanent engraftment donor cell Receiving systemic steroid therapy systemic immunosuppression cyclosporine TNFinhibitors Prior concurrent receipt market investigational agent deem ad hoc basis cause immunomodulation , pose threat permanent engraftment increase risk GVHD . Donor inclusion criterion : Mismatched family donor ( incompatibility 3 locus HLAA , B DR unshared haplotype , higherorder incompatibility ) Age ≥ 16 ≤ 80 year Fit undergo apheresis ( normal blood count , normotensive history stroke ) . Donor test negative HIV1 , HIV2 , hepatitis B virus ( HBV , surface core antigen ) , hepatitis C virus , human Tlymphotropic virus type I/II , Treponema pallidum ( syphilis ) . ECOG performance status 2 less . Adequate vein leukapheresis agree placement temporary central venous catheter . Donor must provide write informed consent . Where multiple equallysuitable donor available , sex mismatch donor prefer . Donor exclusion criterion : Medically uncontrolled coronary heart disease Myocardial infarction within last 3 month History seizure History stroke History malignancy ( except basal cell squamous carcinoma skin , positive PAP smear subsequent negative followup ) Presence transmissible disease ( HIV seropositivity ) Presence major illness suspect systemic dysfunction Presence active inflammatory autoimmune disorder Female donor pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>leukemia</keyword>
	<keyword>myeloid</keyword>
	<keyword>acute</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>allogeneic</keyword>
	<keyword>transient chimerism</keyword>
	<keyword>cell therapy</keyword>
	<keyword>immunotherapy</keyword>
</DOC>